Retraction: Association Between 5‐HTR2C –759C/T (rs3813929) and –697G/C (rs518147) Gene Polymorphisms and Risperidone‐Induced Insulin Resistance Syndrome in an Indian Population

This study was performed to examine the association of 2 functional polymorphisms of the promoter region of the serotonin 5-HTR2C receptor gene: –759C/T (rs3813929) and –97G/C (rs518147) with risperidone-induced insulin resistance syndrome in an Indian population. In this case-control study, 52 adult patients of either sex, having no insulin resistance syndrome before initiating treatment, who were previously drug naive and who received risperidone monotherapy for ≥1 year, were recruited in 2 arms. Of them, 26 had risperidone-induced insulin resistance syndrome, and 26 did not have risperidone-induced insulin resistance syndrome. Polymerase chain reaction and DNA sequencing were performed. Multiple logistic regression analysis was performed, and adjusted odds ratio (AOR) was calculated. The polymorphisms did not deviate from Hardy-Weinberg equilibrium (P > .05). For both rs3813929 and rs518147, the variant (AOR 3.95, 95% CI 0.86-21.9 and AOR 4.12, 95% CI 0.88-23.23, respectively) and the heterozygous (AOR 5.21, 95% CI 0.7-61.38 and AOR 4.26, 95% CI 0.76-31.22, respectively) alleles were associated with risperidone-induced insulin resistance syndrome. The other factors associated with risperidone-induced insulin resistance syndrome were male sex, history of risk factors (ischemic heart disease, diabetes mellitus, or stroke) in family, risperidone dose, pretreatment mean arterial blood pressure, fasting blood glucose, and triglycerides. This is the first study conducted in an Indian population to demonstrate that the 2 functional polymorphisms in the 5-HTR2C gene (rs3813929 and rs518147) are associated with risperidone-induced insulin resistance syndrome.